When a billion-dollar drug trial fails, society learns nothing from the operational process. The detailed documentation of regulatory interactions, manufacturing, and trial design—the "lab notes" of clinical development—is locked away as a trade secret and effectively destroyed, preventing collective industry learning.

The FDA is creating a transparency paradox. It is increasingly publishing complete response letters (CRLs), giving insight into why drugs are rejected. Simultaneously, it has drastically cut the number of public advisory committee (AdCom) meetings held before approval decisions, reducing public input and pre-decision transparency.

Biotech companies are intensely reliant on the FDA for approvals, making it nearly impossible to enforce legal agreements or challenge the agency publicly, even when wronged. This "repeat relationship" means the FDA ultimately holds all the power, making any direct conflict a perilous decision for a company.

Facing a negative FDA decision, Replimune has filed a Freedom of Information Act (FOIA) request to investigate why senior FDA leadership allegedly overruled its own review team. This legalistic tactic moves beyond scientific debate into a public challenge of the agency's internal processes and transparency.

Stelios Papadopoulos claims the biotech industry's public silence on the FDA's dysfunction stems from two core factors: a rational fear of agency retribution against their companies, and a passive hope that future political changes will magically resolve the issues.

A key driver of current FDA turmoil is the stark, real-time contradiction between the agency's published guidelines and its recent decisions. This rapid shifting of regulatory goalposts creates an unprecedented level of uncertainty and frustration for drug developers and investors.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.

Despite political chaos, most FDA work continues. However, companies are experiencing severe inconsistency, with different agency groups offering contradictory advice and major rejections being walked back, as seen with Atara Biotherapeutics. This demonstrates how top-level instability creates unpredictable regulatory hurdles for developers.

An FDA analysis of Complete Response Letters (CRLs) since 2020 revealed that 70% of drug approval rejections were due to CMC issues. This data underscores that manufacturing and control strategies are a primary gatekeeper for regulatory approval, not just clinical trial results.